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Herpes simplex virus type 1 (HSV-1) can maintain a life-long,
persistent infection and cause recurrent mucocutaneous lesions
despite a vigorous immune response to viral components including
envelope glycoproteins. A prevailing rationale for attempts to develop
HSV vaccine has been to amplify such an immune response against
selected envelope glycoproteins (e.g. glycoproteins B and D) that
induce virus-neutralizing antibodies. Despite promising results in
animalmodels, the vaccine constructs based on this concept conferred
limited and short-lasting protection in humans (Corey et al., 1999). It
is therefore of interest to characterize the human immune response to
other viral components such as HSV-1 glycoprotein C (gC) that were
not included in the tested vaccine.
Glycoprotein C (gC1) of HSV-1 is regarded as the major virus
attachment component that mediates binding of the virus to cell
surface heparan sulfate (HS) (Herold et al., 1991; Svennerholm et al.,
1991; Tal-Singer et al., 1995; Trybala et al., 1994; WuDunn and Spear,
1989) or chondroitin sulfate (CS), the latter functioning as an auxiliary
receptor for the gC1-mediated binding activity in the absence of HS
chains (Banﬁeld et al., 1995; Mardberg et al., 2002). It should beemphasized that because gC1 is non-essential for HSV-1 replication in
cultured cells another viral protein can also mediate attachment of
HSV-1 to cells. Grifﬁths et al. (1998) reported that the gC1-deﬁcient
mutants of two HSV-1 strains were not impaired in their binding to
Vero cells, and further data from the same laboratory (Babic et al.,
1999) revealed that gC1-deﬁcient viruses infected cultured mamma-
lian neurons with ﬁve- to tenfold reduced efﬁciency relative to wild-
type gC1-proﬁcient HSV-1. Altogether, available data suggest that the
extent of gC1 involvement in the binding of HSV-1 to cultured cells is
both virus strain and cell type dependent (reviewed by Spear, 2004).
Although non-essential for virus replication in cultured cells, this
glycoprotein seems to provide an important function for viral infec-
tion in humans as probing of almost ﬁve thousand HSV-1 isolates for
the presence of gC1 failed to identify a gC1-deﬁcient variant (Liljeqvist
et al., 1999).
In contrast to what has been reported for several animal
alphaherpesviruses such as pseudorabies virus (Ober et al., 2000),
it is not known whether natural host antibodies to HSV-1 gC1 could
neutralize the virus infectivity in cultured cells. Clariﬁcation of this
issue is complicated by the fact that during HSV-1 infection of most
cell lines, another glycoprotein, i.e. gB, may provide an alternate
attachment function (Herold et al., 1994). In search for limiting cell
culture systems for studies of gC1 functions, we have demonstrated
a gC1-dependency of the HSV-1 binding to mutant mouse L cells
that exhibit selective defect in glycosaminoglycan (GAG) expression
Table 1
Serological characterization of human sera utilized for inhibition of HSV-1 attachment
and infectivity, and for puriﬁcation of gC antibodiesa.
Patient serum IgM HSG gG1 gC1 gG2 HSV typing of isolate
HSV-1posA b10 800 400 100 b100 HSV-1
HSV-1posB b10 N6400 3200 3200 b100 HSV-1
HSV-1posC b10 3200 3200 1600 b100 HSV-1
HSV-1posD b10 6400 1600 3200 b100 HSV-1
HSV-1posE b10 6400 3200 1600 b100 HSV-1
HSV-1posF b10 3200 1600 3200 b100 HSV-1
HSV-2posA 10 800 b100 b100 400 HSV-2
HSV-2posB N160 800 b100 b100 400 HSV-2
HSV-negA b10 b100 n.d.b b100 b100 n.d.b
HSV-negB b10 b100 n.d.b b100 b100 n.d.b
HSV-negC b10 b100 b100 b100 b100 n.d.b
a Serum samples were investigated for presence of IgM antibodies to HSV by
immunoﬂuorescence. HSV IgG antibodies were tested by ELISA using a type-common
HSV antigen (HSG), HSV-1 gG (gG1), HSV-1 gC (gC1), and HSV-2 gG (gG2).
b n.d.: not done.
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be utilized for functional studies of the human antibody response to
gC1.
By using scanning mutagenesis, monoclonal antibody (MAb)-
resistant mutants and peptides speciﬁc for gC1, we have previously
identiﬁed a major HS-binding domain of HSV-1 gC at the N-terminal
part of the protein, comprising aa residues 129-RR-130 and 142-
IRCRFRNSTRMEFRLQIWR-160 as well as another region around G247
(Trybala et al., 1994, Mardberg et al., 2001). In addition, the mucin-
like region of gC1 delimited by aa P33 and G123 was also proposed to
play a vital role in HS-binding activity (Tal-Singer et al., 1995). Later
studies from our group showed that a somewhat enlarged domain
of gC1, encompassing also the residues K114, R117, K120, and I142
conveyed the virus binding to CS, and identiﬁed CS type E units as an
important part of the glycan receptor structure (Mardberg et al., 2002;
Bergefall et al., 2005). Interestingly, an epitope of the anti-gC MAb
B1C1 that is well conserved among clinical HSV-1 isolates may over-
lap the GAG-binding domain of this protein (Trybala et al., 1994,
Liljeqvist et al., 1999; Olofsson et al., 1999; Mardberg et al., 2001).
Previous mapping of this epitope has shown that MAb B1C1 inter-
acted with gC residues R143, R145, T150 and G 247 (Trybala et al.,
1994; Mardberg et al., 2001; Olofsson et al., 1999). Despite this, the
MAbwas previously found to weakly neutralize infectivity of HSV-1 in
cultures of greenmonkey kidney AH1 cells (GMK AH1) (Svennerholm
et al., 1991). In the present report we found that human anti-gC1
antibody and MAb B1C1 neutralized HSV-1 infectivity in human
keratinocyte HaCaT cells, and in mutant L cells expressing HS or CS as
sole cell surface GAGs. Similar activity of MAb B1C1 was also observed
in GMK AH1 cells that had been mildly pre-treated with a HS-
degrading enzyme. Furthermore, human anti-gC antibodies blocked
the binding of the MAb B1C1 to gC, indicating that the human B-cell
response successfully targets the major GAG attachment site of HSV-1
gC. Finally, the experiment estimating the in vivo protective capacity
of anti-gC1 antibodies showed that these antibodies extended
survival time of mice experimentally infected with HSV-1.
Results
Anti-gC antibodies inhibit HSV-1 infection to HaCaT keratinocytes and to
cells expressing restricted GAG types
To investigate the virus-neutralizing activity of human antibodies
speciﬁc for gC of HSV-1, we tested the effect of puriﬁed human anti-
gC1 antibodies on HSV-1 infection of murine L, sog9-EXT1, and gro2C
cells. Human HaCaT cells, i.e. cell line derived from keratinocytes
which are known to be targeted during HSV-1 infection of humans,
and simian GMK AH1 cells were also used in this experiment. Anti-
gC1 antibodies were puriﬁed from sera of three HSV-1 isolation-
positive patients by the gC1-afﬁnity chromatography while sera from
patients infected with HSV-2 only and sera from seronegative subjects
(for description of sera, see Table 1) were used as controls. Pre-
incubation of HSV-1 for 30 min at 37 °C with puriﬁed anti-gC1 anti-
bodies, but not with HSV-2 positive or HSV-negative sera, efﬁciently
neutralized HSV-1 infectivity in CS-expressing gro2C (Fig. 1B) and HS-
expressing sog9-EXT1 (Fig. 1C) cells. In the parental L cells, the virus-
neutralizing capability of anti-gC1 antibodies was slightly reduced as
compared to that observed in gro2C and sog9-EXT1 cells (Fig. 1A).
Anti-gC1 antibodies also neutralized HSV-1 infectivity in HaCaT
keratinocytes (Fig. 1D) but not in GMK AH1 cells (Fig. 1E). Somewhat
more efﬁcient neutralization of HSV-1 infectivity by human anti-gC1
antibodies in gro2C and sog9-EXT1 than in L cells could be related to
the expression of restricted categories of GAG molecules, and to the
fact that unlike L cell sog9-EXT1 produce lesser quantities and rela-
tively undersulfated chains of HS (McCormick et al., 1998). Possible
extension of this conclusion to L or HaCaT cells would require com-
parative analysis of GAGs expressed in these cells and in GMK AH1cells including the amount of GAG produced, chain length and
sulfation pattern.
We also tested the HSV-1 neutralizing activity of murine anti-gC1
monoclonal antibodies (MAbs) B1C1 and C2H12. These MAbs were
tested under experimental conditions similar to these used for human
anti-gC antibodies. MAb B1C1 (Fig. 2A) but not C2H12 (Fig. 2B)
neutralizedHSV-1 infectivity in gro2C, sog9-EXT1, and to lesser extent
in L cells. B1C1 also exhibited the virus-neutralizing activity in HaCaT
but not in GMK AH1 cells. These results indicate that MAb B1C1 and
human anti-gC1 antibodies show similar pattern of neutralization of
HSV-1 infectivity in mutant murine L cells and in HaCaT cells.
Since the here demonstrated neutralization activity was most
clearly shown in mutant cell types with reduced GAG expression, we
then wanted to address the question whether a reduction of the
amount of GAGs on the surface of GMK AH1 cells would render MAb
B1C1 a neutralizing capacity also on this cell type. To this end, GMK
AH1 cells were treated with relatively low concentration (1 U/ml) of
the endoglycosidases heparinase I, heparinase III and chondroitinase
ABC. At this concentration these enzymes reduced weakly or not at all
the HSV-1 infectivity (Fig. 3). Interestingly, the infectivity of HSV-1
was efﬁciently blocked by MAb B1C1 (but not by C2H12) only on cells
pre-treated with heparinase III (Fig. 3), the enzyme that speciﬁcally
cleaves HS linkages at regions with reduced density of chain sulfation.
Anti-gC antibodies reduce HSV-1 attachment to HaCaT keratinocytes
and to cells expressing restricted GAG types
To investigate whether the virus-neutralizing activity of human
anti-gC1 antibodies was due to interference with the virus binding to
cells, antibodies puriﬁed from several human sera were pooled and
tested for their capability to inhibit attachment of puriﬁed radio-
labeled HSV-1 virions to cells. The most efﬁcient reduction of HSV-1
binding by anti-gC1 antibodies was observed in gro2C cells, then
followed sog9-EXT1, HaCaT and L cells, and GMK AH1 cells (Fig. 4A).
Note that this hierarchy was similar to that found with the anti-gC1
antibodies in the virus neutralization assay (Fig. 1).
To further clarify whether anti-gC1 antibodies can neutralize the
virus by interfering with attachment functions of this protein, we also
tested the effects of anti-gC1 MAbs B1C1 and C2H12 on binding of
HSV-1 to cells. B1C1 antibody reduced the virus binding to sog9-EXT1
and gro2C cells substantially (Fig. 4B). Less pronounced reduction in
HSV-1 binding was observed in HaCaT and L cells but not in GMK AH1
cells. In contrast C2H12 antibody affected the virus binding to sog9-
EXT1 cells modestly, and exhibited no inhibitory effects in other cells
(Fig. 4C). Note that in the concentration range of 1 to 10 µg/ml, the
human anti-gC1 antibodies were as efﬁcient in inhibiting the virus
attachment to cells as was the MAb B1C1 (see Figs. 4A and B). The
Fig. 1. Neutralization of the HSV-1 infectivity by puriﬁed human anti-gC1 antibodies in cultured cells. The virus was incubated at 37 °C for 30 min with serial twofold dilutions of
either anti-gC1 antibodies puriﬁed from three HSV-1 positive (HSV-1pos) sera or with sera that contained no anti-gC1 antibodies (HSV-2pos or HSVneg), and the residual viral
infectivity was assayed in L (A), gro2C (B), sog9-EXT1 (C), HaCaT (D), and GMK AH1 (E) cells. The original virus-neutralizing titres of the three HSV-1 positive sera employed for
puriﬁcation of anti-gC1 antibodies were 160, 160, and 640 when assayed in GMK AH1 cells. The results are expressed as a percentage of the number of viral plaque forming units
(PFU) obtained with antibody/serum-treated virus relative to mock-treated controls.
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than the virus binding activity (Fig. 4B) is likely due to the relatively
high quantity of virus used in the attachment assay as the radio-
activity of virus preparations (PFU/cpm) used were ∼100.
Because B1C1MAb and human anti-gC1 antibodies showed similar
inhibitory effects in the virus neutralization (Figs. 1 and 2) and the
virus attachment assays (Fig. 4), we sought to determine whether the
B1C1 epitope overlaps the attachment domain of gC1. To identify an
epitope for the B1C1 antibody, eight different baculovirus-expressed
gC1 constructs were used. Structural details of these recombinant
proteins are schematically outlined in Table 2. In comparison with the
native gC, these fragments contain terminal and/or internal deletions
of long stretches of amino acids. Table 2 also includes a panel of eightsite-altered HSV-1 mutants in gC1 prepared by alanine/threonine/
isoleucine substitution for speciﬁc amino acid (aa) residues of gC1. In
an ELISA assay, all baculovirus-expressed gC1 fragments including the
smallest one (aa 82–209; gGC1-ΔssΔ210) were recognized by MAb
C2H12 (Table 2). Because C2H12 bound to the gC1 fragment carrying
deletion of aa 33–123 (C1-ΔmucTM−H), an epitope for this antibody
seemed to be localized in a gC1 region delimited by aa 124–209.
Indeed, pepscan analysis revealed that the predicted epitope for this
antibody was delimited by aa 201PHVLW205 (data not shown). Note
that this epitope for C2H12 antibody is located outside the gC1
attachment domain (Mardberg et al., 2001, 2002) thus explaining lack
of activity of C2H12 in the virus neutralization and attachment assays
(Figs. 2 and 4). B1C1 MAb showed no reactivity with gC1 constructs
Fig. 2. Neutralization of the HSV-1 infectivity by anti-gC1 monoclonal antibodies in
cultured cells. The virus was pre-incubated at 37 °C for 30 min with serial twofold
dilutions of monoclonal antibody B1C1 (A) or C2H12 (B) and the residual virus
infectivity assayed in L, gro2C, sog9-EXT1, HaCaT, or GMK AH1 cells. The results are
expressed as a percentage of the number of viral plaque forming units (PFU) obtained
with antibody/serum-treated virus relative to mock-treated controls.
Fig. 3. The effect of anti-gC1 monoclonal antibodies (MAbs) on neutralization of the
HSV-1 infectivity in enzyme-treated GMK AH1 cells. The virus was pre-incubated at
37 °C for 30 min with MAb B1C1 or C2H12 at the concentration of 20 µg/ml. The
residual virus infectivity was assayed in GMK AH1 cells that had been pre-treated
with 1 U of either heparinase I (Hep-I), heparinase III (Hep-III), chondroitinase ABC
(Chon-ABC) or the enzyme mixture (Hep-I+Hep-III+Chon-ABC). The results are
expressed as a percentage of the number of viral plaque forming units (PFU) obtained
with antibody-treated virus on enzyme-treated or non-treated cells relative to the
number of HSV-1 plaques formed in the absence of MAb in mock-treated cells.
Fig. 4. Effect of human anti-gC1 antibodies or murine anti-gC-1 monoclonal antibodies
(MAbs) on attachment of HSV-1 to cells. Puriﬁed radiolabeled virus was incubated at
4 °C for 30 min with speciﬁc concentrations of puriﬁed pulled human anti-gC1 anti-
bodies (A) or MAbs B1C1 (B), or C2H12 (C), and the mixtures were tested for residual
virus binding in L, gro2C, sog9-EXT1, HaCaT, or GMK AH1 cells. The results are
expressed as a percentage of the number of attached counts-per-minute (cpm)
obtained with antibody-treated virus relative to mock-treated controls. Two separate
experiments were performed in duplicate for each antibody/serum sample.
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gesting that its epitope or part of it is located outside this region, or
that B1C1 epitope is dependent on conformation of gC1. The latter
possibility was supported by the pepscan analysis that failed to iden-
tify a linear epitope for this MAb (data not shown). However, binding
of B1C1 to the site-alteredmutants in gC, revealed lack of its reactivity
Table 2
Reactivity of anti-gC monoclonal antibodies with baculovirus-expressed gC fragments as well as mutant gC proteins altered at speciﬁc amino acid residuesa.
a The top eight constructs are speciﬁc fragments of gC1 expressed in baculovirus system (prepared in this work) while the remaining proteins are mutant gC1 carrying speciﬁc
amino acid substitutions (Mardberg et al., 2001, 2002; Trybala et al., 1994). In the schematic structure of the C1-full the numbering concerns aa positions of signal sequence (ss),
cysteine residues (C), and terminal aa of the proteins. The positions of N-linked glycans are depicted with umbrellas. Presence of the His-tag is illustrated by linear sequence of
six histidines (H). Solid boxes at the amino-terminal end in constructs gGC1-ΔssΔ302 and gGC1-ΔssΔ210 denote replacement of native ss of gC1 with ss derived from gG of
pseudorabies virus.
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155, threonine 150, but not these altered at isoleucine 142 and
phenylalanine 146 (Table 2) suggesting that speciﬁc arginine residues
and threonine 150 are included in the B1C1 epitope. This observation
was veriﬁed by the treatment of gC1with p-hydroxyphenylglyoxal, an
arginine blocking agent, which diminished the binding to gC1 of MAbB1C1 but not MAb C2H12 whose epitope, as reported above, did
not contain arginines (data not shown). Given the fact that arginine
residues at positions 143, 145, 147, 151 and 155, as well as isoleucine
142 and phenylalanine 146 are known to be important for binding of
gC1 to HS/CS (Mardberg et al., 2001, 2002), the B1C1 epitope seemed
to selectively include speciﬁc aa residues from the attachment domain
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1994) thus being similar but not identical to this functional site.
We also testedwhether human sera containing anti-gC1 antibodies
could interfere with binding of B1C1 to puriﬁed gC1. The human sera
collected from ﬁve of the six HSV-1 seropositive subjects, but not sera
drawn from the two HSV-2 seropositive patients or from the three
seronegative subjects inhibited the binding of B1C1 to gC1 (Fig. 5A). It
should be noted that the serum designated as HSV-1posA, which did
not inhibit B1C1 binding, was almost devoid of anti-gC1 antibodies as
judged from ELISA results (Table 1). In contrast, the binding of MAb
C2H12 to gC1 was only marginally inhibited by the human antibodies
(Fig. 5B). These results indicate that human HSV-1 immune sera con-
tained antibodies targeting epitope(s) on gC1 similar to that of B1C1
MAb. Because the B1C1 epitope overlaps a part of the attachment
domain of gC1 (see above), we conclude that the human B-cell response
recognizes and strongly reactswith the region of gC1 responsible for the
attachment of HSV-1 to cell surface HS/CS receptors.
Anti-gC antibodies protect mice from HSV-1 infection
To investigate whether anti-gC MAbs could protect mice from
HSV-1 infection, the neurotropic 2762 strain of HSV-1 (Bergstrom et al.,
1990) was pre-incubated for 30 min at 37 °C withMAb B1C1, C2H12 orFig. 5. The effect of gC1-antibody containing human sera on binding of murine MAbs to
gC1. The HSV-1 positive sera with anti-gC1 antibody titers ranging from 100 to 3200 or
human sera containing no detectable anti-gC1 antibodies (at titer of b100) were
incubated at 37 °C for 2 h with puriﬁed gC1 coated to plastic surface. Subsequently
MAbs B1C1 (A) or C2H12 (B) were added and tested for binding to gC1. Shown
in parentheses are values of anti-gC1 antibody titers. The results are expressed as a
percentage of absorbance value obtained with MAb bound to serum-pre-treated
gC1 relative to mock-treated controls. Two separate experiments were performed in
duplicate for each antibody/serum sample.irrelevant mouse IgG1 MAb prior to intraperitoneal inoculation into
BALBc mice. Each animal in groups of 10 received 5 µg of antibody and
100 or 500 PFU of the virus. In comparison with mice that received
irrelevant controlMAb, B1C1 but not C2H12 antibody extended survival
of mice inoculated with either 100 or 500 PFU (Fig. 6).
Preliminary experiment in which 5 mice received by the same
route a mixture of human anti-gC1 antibodies (20 µg) and 100 PFU of
HSV-1 2762 strain, revealed that while all 5 animals in control group
died after 5 days of infection, all animals that received human anti-gC1
antibodies survived until the end of experiment at the day 20 (data not
shown). Although these experiments were performed with the use of
HSV-1 strain that was not employed in our cell culture assays, and a
route of virus inoculation did not correspond to the known sites of
primary HSV-1 infection of humans, the results indicate that murine
B1C1 MAb or human anti-gC1 antibodies are capable of neutralizing
HSV-1 infectivity in mice.
Discussion
Viral envelope glycoproteins are prominent targets for the host
immune response and often utilized as antigens for serological assays
and for immunization studies. HSV-1 gC is no exception to the rule, as
it constitutes a major antigen for both the B- and T-cell responses.
Although the antibodies to this protein develops relatively late during
primary infection as compared to gB and gD, patients with recurrent
herpetic lesions were reported to show increased IgG antibody reac-
tivity to gC (Arvin et al., 1983). Furthermore, gC was early found toFig. 6. The HSV-1 neutralizing activity of B1C1 monoclonal antibody in mice. B1C1,
C2H12, or irrelevant IgG monoclonal antibody was pre-incubated of HSV-1 strain 2762
prior to intraperitoneal inoculation of mice. Mice in groups of 10 received 500 (A) or
100 (B) plaque forming units (PFU) of the virus along with 5 µg of antibody. The results
are expressed as a percentage of survived mice observed daily within the time of two
weeks of experiment.
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(Glorioso et al., 1985). However, in contrast to reports on some animal
herpesviruses showing that immunity to gC may control infection in
vivo (Ober et al., 2000; Gupta et al., 2001), the dispensability of HSV-1
gC for cell culture infection reported in some studies may have led to
the erroneous assumption that gC antibodies are of less interest in
comparison to the more widely studied indispensable glycoproteins
as concerns induction of protective immunity to HSV-1. Here we
show that in human HaCaT keratinocytes and in a cell culture
model where gC plays a crucial role for attachment and infectivity,
human antibodies to this protein are efﬁcient inhibitors of viral
infection. Furthermore the anti-gC MAb B1C1, which is known to be a
potent inhibitor of HSV-1 attachment to cells (Svennerholm et al.,
1991) and whose epitope is completely conserved among HSV-1
strains (Liljeqvist et al., 1999), was found to be neutralizing in HaCaT
keratinocytes, in cells exhibiting a restricted expression of GAGs, i.e.
either HS or CS (sog9-EXT-1 and gro2C cells, respectively), or, in cells
subjected to a modest endoglycosidic trimming of HS chains with
heparinase III (GMK-AH1 cells). These results suggest that an ample
expression of GAGs on surfaces of some cultured cells such as GMK
AH1 prevents neutralization of HSV-1 infectivity by anti-gC1 anti-
bodies. It has been reported that digestion of GMK AH1 (Trybala et al.,
2000) or HEp-2 (Herold et al., 1994; Mardberg et al., 2001) cells with
heparinase I rendered these cells less susceptible to infection with the
gC1-deﬁcient mutants than the wild-type HSV-1 implying that
cleavage of HS chains reduces the binding sites for the gC-inde-
pendent attachment of HSV-1 to cells. However in HEp-2 (Herold et
al., 1994) or GMK AH1 (Adamiak, unpublished data) cells treated with
heparinase III these differenceswere either absent or less pronounced.
Heparinase I and III are known to target weakly and extensively
sulfated stretches of HS chain respectively, however, identiﬁcation of
a domain structure of the non-digested cell-associated fragments of
HS is difﬁcult due to the lack of satisfactory methods of HS chain
sequencing (Korir and Larive, 2009). Hence, as data on the CS and HS
composition of mutant L cells, HaCaT and GMK AH1 cells are currently
incomplete, we cannot yet deﬁne a common GAG denominator for
this anti-gC1 antibody dependent neutralization, but we suggest that
highly sulfated stretches of HS chain are required and maybe are
better exposed after digestion of GMK AH1 cells with heparinase III.
These results also suggest that the extent of gC-dependency in the
binding of HSV-1 to cells (Herold et al., 1991; Grifﬁths et al., 1998; Tal-
Singer et al., 1995; Trybala et al., 1994), whichwas suggested to be the
virus strain and the cell type dependent (reviewed by Spear, 2004)
can be primarily affected by the abundant GAG expression on the
surface of cultured cells or the presence of speciﬁc structures in GAG
chains. Recognition of GAGs is known to offer a selective advantage for
replication of some viruses in cultured cells (reviewed in Trybala et al.,
2002) but not in their natural hosts most likely due to a less restricted
expression of GAGmolecules in in vitro growing cells. It is known that
components of culture media may affect expression and ﬁne structure
of GAG chains (e.g. Brown et al., 1999; Morano et al., 1999).
Mapping of the MAb by the use of baculovirus-expressed gC
fragments showed that a shorter fragment encompassing a major
GAG-binding domain was insufﬁcient for binding of MAb B1C1, while
a longer fragment including the carboxyterminal part of antigenic site
II of gC (Wu et al., 1990) fulﬁlled both these two functions. Together
with data from pepscan analysis that easily provided an epitope for
the MAb C2H12 reactive with a continuous stretch of aa residues but
failed to demonstrate a reactivity of the MAb B1C1 to any peptide, we
conclude that a large portion of the N-terminal part of gC is necessary
to achieve the proper conformation needed for B1C1 binding and that
the epitope is overlapping but not identical with the GAG-binding
domain of gC.
Given a restricted system for study of HSV-1 attachment in form of
gro2C cells or sog9 EXT-1 cells, gC antibodies puriﬁed from human
sera did inhibit viral binding to the cell surface, albeit at low dilutions.Most likely, this inhibition was caused by interference with viral
binding to GAG molecules by gC. Thus we conclude that under condi-
tions where gC function is necessary for viral binding, human anti-
bodies can block this activity. Possibly, the anti-gC antibodies have a
similar potency in vivo, considering the prominent B-cell response to
this protein in infected individuals (Arvin et al., 1983). When the
question as to whether human anti-gC sera contain antibodies whose
epitopes overlap that of B1C1was investigated, almost all sera blocked
binding of the MAb to gC. One cannot exclude that human anti-gC1
antibodies represent a set of polyclonal antibodies which recognize
different domains of gC1 and someof these clonesmay outperform the
activity of MAb B1C1. We interpret this ﬁnding as a strong indication
that the humanB-cell response targets theGAG-binding domain on gC,
since the epitope of B1C1 shared several amino acid residues with this
functional domain. It is of interest that this interaction, in addition to
an effect in cell lines reduced inGAG expression, also inﬂuencedHSV-1
attachment to and infectivity of human keratinocytes, which are
target cells for the natural infection of this virus. The importance of
gC function for infection of human keratinocytes by another alpha-
herpesvirus, e.g. varicella-zoster virus (Moffat et al., 1998) under-
scores the need for further studies on the role of HSV-1 gC on early
interactions with these cells.
Materials and methods
Cells and viruses
African greenmonkey kidney cells (GMK AH1)were propagated in
Eagle's minimum essential medium (EMEM) supplemented with 2%
newborn calf serum and 0.05% Primaton RT substance. Human skin
keratinocyte (HaCaT) cells (Boukamp et al., 1988) were propagated in
Dulbecco's modiﬁed EMEM (DMEM) supplemented with 10% fetal
calf serum, 1% L-glutamine and antibiotics. These cells were used in
experiments as monolayer cultures after 4–6 days of propagation.
Murine L, gro2C, and sog9-EXT1 cells were kindly provided by Dr.
Frank Tufaro, University of British Columbia, Vancouver. The gro2C
cells (Gruenheid et al., 1993) were derived from L cells through
selection pressure by lytic HSV infection, and appeared to be deﬁcient
in HS- but proﬁcient in CS-expression on cell surfaces. Further selec-
tion pressure by HSV infection resulted in the HS/CS-deﬁcient cell line
sog9, and its HS-expression rescued variant sog9-EXT1 (McCormick
et al., 1998) was used in the present study. These cells were grown in
DMEM supplemented with 10% fetal calf serum. For culture of Sog9-
EXT1 cells the medium was supplemented with geneticin to maintain
cells with the transfected EXT1 gene. HSV-2 333 strain (Duff and Rapp,
1971), HSV-1 KOS 321 strain (Holland et al., 1983), the gC-negative
derivative of KOS 321 designated gC−39 (Holland et al., 1984), and
the HSV-1 mutants prepared by transfection of altered gC into gC−39
(Mardberg et al., 2001) were used throughout the study.
Construction of baculovirus-expressed fragments of HSV-1 gC
The following fragments of HSV-1 gC were prepared (Table 2).
(i) Baculovirus-expressed complete gC (C1-full), was prepared by
cloning the Nhe I (814)–Sph I (2571) 1758 bp fragment from the
plasmid pGC (kindly provided by Dr. J. Glorioso, Pittsburgh School of
Medicine, University of Pennsylvania) into the baculovirus transfer
plasmid, pFastBac1 under the polyhedrin promoter. (ii) gC fragment
without transmembrane and endodomain sequences (C1-TM−H) and
gC fragment comprising amino acids 1–209 (C1-Δ210H) were con-
structed by PCR using pGC as a template with forward primer for
both fragments 5′tagactagtctgccgggaacgctagccgatccctc3′ and reverse
primers 5′ttttctgcagttaatgatgatgatgatgatgctcgatcgcctcgatca3′ (for C1-
TM−H) and 5′ttttctgcagttaatgatgatgatgatgatgggccccctccgcccagag3′
(for C1-Δ210H). The forward primer was designed to contain the
SpeI restriction site while the reverse primers were projected to
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and by the sequence recognized by PstI restrictase. The SpeI–PstI 1503
and 703 bp fragments were ligated into linearized transfer vector.
(iii) Constructs carrying internal in-frame deletions of regions coding
for mucin-like region (amino acids 33–123) or another part of gC
ectodomain (amino acids 360–453) were prepared by digestion of C1-
TM−H fragment with XbaI followed by ﬁlling in the protruding ends
with Klenow fragment polymerase, cleavage with NruI and re-ligation
(C1-Δ360H) or by digestion of the same template with ApaI and re-
ligation (C1-ΔmucTM−H) (Tal-Singer et al., 1995). Both these proce-
dures were combined to prepare construct with both these deletions
(C1-ΔmucΔ360H). (iv) The gC fragment comprising amino acids 65–
301 (gGC1-ΔssΔ302) was prepared by digestion of pGC with TaqI at
nucleotides 1039 and 1753, cloning into pFastBacssgG plasmid
(obtained by fusion of pFastBac1 with the PRV gG signal sequence).
(v) The gC fragment comprising amino acids 82–209 (gGC1-ΔssΔ210)
was prepared by digestion of pGC with NaeI at nucleotides 1090 and
1475 and cloning into pFastBacssgG. All recombinant transfer vectors
were analysed by digestion with endonucleases and were used to
generate recombinant baculoviruses according to manufacturer's pro-
tocol (Bac-to-Bac Expression System; Life Technologies). Baculovirus-
expressed fragments of gC comprisingHis-tagwere puriﬁed byNi-NTA-
afﬁnity chromatography while all other fragments by immunoafﬁnity
chromatography using MAb B1C1 or C2H12.
Site-directed mutagenesis of HSV-1 gC
The assay was performed by using Promegas Altered Sites II in
vitro Mutagenesis System (Scandinavian Diagnostic Services, Falken-
berg, Sweden) as described previously (Mardberg et al., 2001). Brieﬂy,
the pAltgC plasmid that contained an insert of 639 bp of HSV-1 gC
DNA was used as a template for site-speciﬁc alterations. Mutagenesis
primers (Scandinavian Gene Synthesis, Koping, Sweden) were de-
signed to convert positively charged and hydrophobic amino acids in
the N-terminal part of gC to alanines and threonines, respectively.
Template with conﬁrmed alterations was subcloned into plasmid pGC
and then co-transfected with gC−39 (a gC-null mutant) genomic DNA
into vero cells. Mutant viruses with recombined gC protein were
identiﬁed and puriﬁed to homogeneity by using an immunoreactive
black plaque assay. The list of mutated variants is shown in Table 2.
Puriﬁcation of virus particles and viral envelope glycoprotein gC
Methyl 3H-thymidine labelled virionswere puriﬁed from infectious
culturemedia of GMKAH1 cells by centrifugation through a three-step
discontinuous sucrose gradient (Karger and Mettenleiter, 1993).
Relative amounts of virions in preparations of puriﬁed virus were
evaluated by comparing DNA contents (Karger et al., 1995). The viral
gC was puriﬁed by immunoafﬁnity chromatography as described
previously (Trybala et al., 2000) using the MAb B1C1 (Olofsson et al.,
1999). To minimize the amount of detergent in puriﬁed viral proteins,
the columns were washed with detergent-free washing buffer just
prior to the elution of the protein.
Anti-gC antibodies and their reactivity
Sera, listed in Table 1, were collected from six patients suffering
from oral herpetic lesions that were isolation-positive for HSV-1. Sera
from two patients infected with HSV-2 only and sera from three
seronegative subjects were used as controls. Presence of antibodies
speciﬁc for HSV and speciﬁc HSV glycoproteins was tested by an
ELISA-based method. Antibodies speciﬁc for HSV-1 gC were isolated
from human sera by the gC-afﬁnity chromatography according to the
procedure described earlier for HSV-2 gG (Liljeqvist et al., 1998),
using puriﬁed gC as sorbent.The anti-gC MAbs used were B1C1 MAb previously suggested to
recognize a discontinuous type-speciﬁc epitope overlapping themajor
GAG-binding domain at the N-terminal part of gC (Trybala et al., 1994;
Olofsson et al., 1999; Mardberg et al., 2001), and the type-common
MAb C2H12 (Bergstrom et al., 1992; Sjoblom et al., 1992) which is
reactive in immunoblotting and therefore most likely recognizes a
linear epitope. Veriﬁcation of the presence of arginine residue in aMAb
epitopewas carried out as described by Yamasaki et al. (1980). Brieﬂy,
puriﬁed gC, pre-adsorbed to the plastic surface, was treated with
speciﬁc concentrations of p-hydroxyphenylglyoxal, a substancewhich
chemically modiﬁes the guanidyl group of the arginine residue
(Yamasaki et al., 1980). After washing, residual reactivity of gC with
MAbs was tested by an ELISA-based method.
Pepscan analysis of anti-gC MAbs and puriﬁed human anti-gC antibodies
The anti-gCMAbs B1C1 and C2H12were tested for their binding to
a panel of overlapping peptides prepared on a continuous cellulose
support (13-mers with 11 amino acids overlaps), (Jerini Bio Tools)
according to a standard spot synthesis protocol (Frank, 1992; Kramer
et al., 1994). The peptides covered the aa 121 to 300 of the gC protein
and the sequences were deduced from nucleotide sequence data
derived from strain KOS 321. The cysteine residues were replaced by
serines to avoid oxidation during the incubation steps. The membrane
was washed in methanol and three times in Tris-buffered saline (TBS)
containing 0.05% Tween-20, pH 8.0 (T-TBS) and incubated overnight
with blocking buffer (Genosys Biotechnologies) diluted 1:10 in T-TBS
supplemented with 50 mg/ml of sucrose. The respective MAb, diluted
in blocking buffer to a concentration of 1 µg/ml was added and incu-
bated with a membrane for 3 h at room temperature. After triple
washing, peroxidase-conjugated rabbit anti-mouse IgG (Dako) was
added in blocking buffer at a concentration of 1 µg/ml and incubated
for 2 h. The membrane was developed with ECL-detection solution on
X-Omat S ﬁlm.
HSV attachment-inhibition assay
Monolayer cultures of cells growing in 96-well cluster plates were
precooled to 4 °C. The cells were washed with PBS (137 mM NaCl,
2.7 mM KCl, 8.1 mM Na2HPO4, 1.5 mM KH2PO4) supplemented with
1 mMCaCl2 and 0.5 mMMgCl2 (PBS-A) and blocked for 1 hwith PBS-A
containing 1% bovine serumalbumin. Radiolabeled viral particleswere
mixed with speciﬁc concentrations (0–56 μg/ml) of anti-gC MAb and
incubated at 4 °C for 30 min. Thereafter, the mixtures were added to
cells and virus adsorptionwas allowed for 1 h at 4 °C. Subsequently the
cells were washed three times with PBS-A, lysed with 0.2 ml of PBS
containing 5% SDS, and ﬁnally transferred to scintillation vials for
quantiﬁcation of radioactivity.
HSV-1 plaque-reduction assays
Effect of human sera, puriﬁed human anti-gC IgG antibodies, and
murine anti-gC MAbs on HSV infectivity was tested as follows.
Conﬂuent monolayers of 2–3 days old cells in 6 well plates were
washed twicewith 2 ml of Dulbecco'smodiﬁed Eaglemedium. Twoml
portions of the samemedium containing 0.2 % of HSV-negative human
serum as well as indicated dilutions of the test sera (inactivated at
56 °C for 30 min) or puriﬁed antibodies were pre-incubated with
approximately 200 plaque forming units (PFU)/ml of the virus (KOS
321) for 30 min at 37 °C. One ml portions of the mixture were added
per well and left for adsorption for a further 1 h min at 37 °C. The cells
were then washed twice with 2 ml of the medium and overlaid with
3 ml of 1%methylcellulose solution in the samemedium. After incuba-
tion for 4–5 days at 37 °C the cells were stained with 1% solution of
crystal violet to visualise the viral plaques.
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degrading enzyme pre-treated GMK AH1 cells was carried out as
follows. Conﬂuent monolayers of 3 day old GMK AH1 cells in 12 well
plates were washed twice with 1 ml of Eagle's medium, and 0.5 ml
portions of the same medium containing 0.2% BSA and 1 U/ml of
heparinase I (Sigma) or heparinase III (Sigma) or chondroitinase ABC
(Sigma) or the mixture of all of these enzymes was added to the cells.
The cells were left for the digestion at 37 °C for 1 h. One ml portions of
Eagle's medium containing 0.2% of HSV-negative human serum as
well as 20 µg/ml of anti-gC-1 MAb were pre-incubated with approxi-
mately 200 PFU of KOS 321 for 45 min at 37 °C, and 0.5 ml portions of
the virus-MAb mixture were added to cells and left for adsorption for
a further 30 min at 37 °C. The rest of the procedure was as described
above.
Effect of puriﬁed human anti-gC antibodies on binding of B1C1 MAb
to gC
A MAb-inhibition assay using human sera was performed as
described previously (Ross et al., 1985). Puriﬁed gC was coated onto
96-well plates (Maxisorp) in carbonate buffer, pH 9.6. Subsequently,
serial tenfold dilutions of human sera showing reactivity to HSV-1 or
HSV-2, or being seronegative to HSV (see Table 1 for characterization)
were added to pre-adsorbed gC and incubated at 37 °C for 2 h. MAbs
B1C1 or C2H12 were added to the same wells to obtain a ﬁnal con-
centration of 70 and 20 ng/ml, respectively. Following overnight
incubation of themixtures at 37 °C, the plateswere rinsed and alkaline
phosphatase-conjugated goat anti-mouse antibodies (Jackson) were
added. Following addition of the substrate, absorbance values were
read at 405 nm.
HSV-1 infection of mice in the presence of anti-gC MAbs
HSV-1 strain 2762 (Bergstrom et al., 1990) at ﬁvefold dilutions in
HanksmediumwasmixedwithMAbB1C1, C2H12 or irrelevantmouse
IgG1 (namelyV-38 3C4B4E2) antibody (all at 10 µg/ml) and incubated
at 37 °C for 30 min. All mixtures were supplemented with 0.2% mouse
HSV-negative serum for protection of virus infectivity during the
incubation. Approximately 0.5 ml of this mixture containing 5 µg of
antibody and 100 or 500 viral PFU was inoculated intraperitoneally
into 4–6 week old BALBc mice. The mice were observed daily for
14 days for the presence of the virus-induced symptoms.
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